==== Front
Int J Chron Obstruct Pulmon DisInt J Chron Obstruct Pulmon DisInternational Journal of COPDInternational Journal of Chronic Obstructive Pulmonary Disease1176-91061178-2005Dove Medical Press 10.2147/COPD.S178410copd-13-2253ErratumFactors associated with appropriate inhaler use in patients with COPD – lessons from the REAL survey [Erratum] 2018 25 7 2018 25 7 2018 13 2253 2254 © 2018 Price et al. This work is published and licensed by Dove Medical Press Limited2018The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
==== Body
Price D, Keininger DL, Viswanad B, et al. Int J Chron Obstruct Pulmon Dis. 2018;13:695–702.

The author has advised that several changes need to be made to the paper.

Page 698, Figure 1 should be replaced by:

Page 699, Results section, Left column, Second paragraph, “Of the patients who did not feel confident, more patients reported overdosing with Genuair, Ellipta, and Respimat (33.2%, 29.4%, and 21.4%, respectively).” should read “Of the patients who did not feel confident, more patients reported overdosing with Genuair, Ellipta, and Respimat (35.2%, 29.4%, and 21.4%, respectively).”

Page 700, Discussion section, Right column, Fourth paragraph, “Limitations of the survey were that measures of patient adherence were based on patient report. Additionally, there may have been possible selection bias and recall bias. The survey was also not a randomized trial and reflected real-world experience.” should read “All possible efforts were made to ensure that the data received on Respimat were referring to tiotropium and not the use of short-acting bronchodilators; however this needs to be considered as a limitation of this analysis. Further limitations of the survey were that measures of patient adherence were based on patient report. Due to the nature of the trial, there might have been some recollection bias of some patients in specific countries, which indicated using the Respimat device longer than it had been approved. Additionally, there may have been possible selection bias and recall bias. The survey was also not a randomized trial and reflected real-world experience.”

Page 701, Figure 4 should be replaced by:

Figure 1 Length of use by device.

Figure 4 Proportion of device correct dosing.